Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Ernexa Therapeutics Inc. (ERNA) had Stock-Based Compensation of $1.71M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-14.10M |
|
-- |
|
-- |
|
$9.32M |
|
$-9.32M |
|
$-4.81M |
|
$-14.13M |
|
$-14.13M |
|
$-14.08M |
|
$-14.08M |
|
$-14.08M |
|
$-14.08M |
|
$-9.32M |
|
$-9.06M |
|
0.25M |
|
0.25M |
|
$-56.00 |
|
$-56.00 |
|
| Balance Sheet Financials | |
$3.13M |
|
$0.09M |
|
$2.70M |
|
$5.83M |
|
$3.11M |
|
-- |
|
$0.32M |
|
$3.43M |
|
$2.40M |
|
$0.36M |
|
$2.40M |
|
0.31M |
|
| Cash Flow Statement Financials | |
$-7.02M |
|
$-0.04M |
|
$7.21M |
|
$1.73M |
|
$1.88M |
|
$0.15M |
|
|
Stock-Based Compensation |
$1.71M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.05M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-586.83% |
|
-3945.10% |
|
-241.41% |
|
-586.59% |
|
$7.64 |
|
$-27.96 |
|
$-27.81 |
|